科学家创业9年,烧钱8亿元!对赌上市倒计时仅剩1年,深陷专利纠纷的麦济生物如何撑起26亿元估值?

每日经济新闻
Dec 23, 2025

临近年末,对递表港交所近半年却仍未进入聆讯的IPO(首次公开发行股票)公司而言,上市冲刺失败几率正在放大。   麦济生物就是其中之一。公司今年7月14日向港交所提交上市申请书,截至目前尚未进入聆讯。自2016年成立以来,麦济生物已自主研发并建立一条由八款创新候选产品组成的管线。其中,核心产品MG-K10为一款长效抗IL-4Rα抗体,今年10月30日已获得中国国家药监局(NMPA)的上市申请受理。 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10